1. Home
  2. VRAX vs BCDA Comparison

VRAX vs BCDA Comparison

Compare VRAX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • BCDA
  • Stock Information
  • Founded
  • VRAX 2013
  • BCDA N/A
  • Country
  • VRAX United Kingdom
  • BCDA United States
  • Employees
  • VRAX N/A
  • BCDA N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • BCDA Health Care
  • Exchange
  • VRAX Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • VRAX 7.3M
  • BCDA 7.9M
  • IPO Year
  • VRAX 2022
  • BCDA N/A
  • Fundamental
  • Price
  • VRAX $1.90
  • BCDA $2.84
  • Analyst Decision
  • VRAX
  • BCDA Strong Buy
  • Analyst Count
  • VRAX 0
  • BCDA 1
  • Target Price
  • VRAX N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • VRAX 293.5K
  • BCDA 55.7K
  • Earning Date
  • VRAX 02-05-2025
  • BCDA 03-26-2025
  • Dividend Yield
  • VRAX N/A
  • BCDA N/A
  • EPS Growth
  • VRAX N/A
  • BCDA N/A
  • EPS
  • VRAX N/A
  • BCDA N/A
  • Revenue
  • VRAX $84,872.00
  • BCDA $71,000.00
  • Revenue This Year
  • VRAX $5,169.18
  • BCDA N/A
  • Revenue Next Year
  • VRAX $66.97
  • BCDA N/A
  • P/E Ratio
  • VRAX N/A
  • BCDA N/A
  • Revenue Growth
  • VRAX 7.03
  • BCDA N/A
  • 52 Week Low
  • VRAX $0.60
  • BCDA $1.63
  • 52 Week High
  • VRAX $9.00
  • BCDA $8.85
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 49.13
  • BCDA 67.71
  • Support Level
  • VRAX $1.58
  • BCDA $2.27
  • Resistance Level
  • VRAX $2.10
  • BCDA $2.78
  • Average True Range (ATR)
  • VRAX 0.25
  • BCDA 0.26
  • MACD
  • VRAX 0.01
  • BCDA 0.04
  • Stochastic Oscillator
  • VRAX 47.88
  • BCDA 86.90

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: